Vivoryon Therapeutics AG Stock Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
Sales 2023 | -3.62K -3.87K -5.29K | Sales 2024 * | - | Capitalization | 20.85M 22.3M 30.48M |
---|---|---|---|---|---|
Net income 2023 | -28M -29.94M -40.93M | Net income 2024 * | -18M -19.25M -26.31M | EV / Sales 2023 | -53,497 x |
Net cash position 2023 | 18.52M 19.81M 27.08M | Net cash position 2024 * | 19.55M 20.9M 28.58M | EV / Sales 2024 * | - |
P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.12
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.56% |
Latest transcript on Vivoryon Therapeutics AG
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |